About Event

Thank you to our speakers, sponsors, and delegates who joined us for the online summit! If you are interested in the 2023 event, please get in touch at info@hansonwade.com

Heart failure affects about 6.2 million people in the United States, with half of the patients having heart failure with preserved ejection fraction (HFpEF) and counting. Yet, there is no treatment for this form of the disease as HFpEF is a heterogeneous syndrome and, like other disease areas, this makes it difficult to develop effective therapeutics that will work for patients in each of the subtypes.

The HFpEF Drug Discovery & Development Summit is the first industry-specific forum exclusively focused on showcasing the latest drug development and translational research in HFpEF and its relationship with metabolic syndromes and co-morbidities, whilst giving you the pivotal insights you need to kickstart the next generation of clinically defining therapeutics for HFpEF to avoid late-stage clinical trial failures.

With 20+ hours of content, an interactive workshop, and over 5 hours of networking with key industry leaders from Amgen, Cardiobiopharma, AstraZeneca, NeoProgen, Eli Lilly, Bayer, Novartis and more, this comprehensive forum will completely focus on innovative research and state of the art science in HFpEF and the current challenges and opportunities in the field.

Network with 80+ senior CSOs, CEOs, research scientists, and academics committed to tackling this form of heart failure and provide a meaningful impact on the lives of over 3.1 million patients suffering from HFpEF worldwide.

Unmissable Highlights Included:

Learned the outcomes of EMPEROR-Preserved with Boehringer Ingelheim to set up future trials for success

Investigated the relationship of other comorbidities with HFpEF, with AstraZeneca and Novo Nordisk providing a holistic overview of patient health

Uncovered Next-Generation Regulatory Genome Targets for Cardiac Fibrosis and other emerging therapeutics with HAYA Therapeutics to revive your therapeutic approach and treat HFpEF more successfully.

Scrutinized common mistakes biopharma make when exploring new therapeutic targets and learn how to avoid them with Dr Sheldon Litwin to understand how to design & execute a foolproof plan to successfully identify & validate new HFpEF patients.

Analyzed current evaluations for quality of life for HFpEF patients and the major impact of fine-tuning this definition alters the drug development industry